Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

 Company News
Medivir AB (MVRBF): Optimization Of Capital Structure 10/16/2014 1:53:36 PM
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014 8:33:57 AM
Medivir AB (MVRBF) Capital Markets Meeting on 16 October 2014 10/7/2014 1:28:50 PM
Medivir AB (MVRBF): Interim Report, January – June 2014* 8/21/2014 8:32:57 AM
Ex-Merck & Co., Inc. (MRK) Exec Appointed New President And CEO Of Medivir AB (MVRBF) 8/11/2014 6:15:44 AM
Medivir AB (MVRBF) Licenses Respiratory Syncytial Virus Drug Program From Boehringer Ingelheim Corporation 8/4/2014 11:04:25 AM
Medivir AB (MVRBF): Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day 7/28/2014 8:56:00 AM
Medivir AB (MVRBF): FDA Has Granted Priority Review For OLYSIO® In Combination With Sofosbuvir Supplementary New Drug Application 7/15/2014 8:19:07 AM
Beactica Initiates Drug Discovery Collaboration With Medivir AB (MVRBF) 6/10/2014 11:05:26 AM
Medivir AB (MVRBF) Release: OLYSIO™ Available Soon In All Nordic Countries For The Treatment Of Adults With Hepatitis C Genotype 1 And 4 Infection 6/10/2014 8:56:08 AM